are not surprisingly excellent, even at 5 years. However, the key unanswered question, with almost no data, concerns the durability of remission after stopping ibrutinib in a deep but probably not complete remission, as compared with continuing ibrutinib. This durability may ultimately differ based on depth of response, duration of therapy, and CLL prognostic factors, but as yet, it remains unknown. Further follow-up of patients who discontinue without disease progression, as well as systematic investigation of time-limited therapy, including novel likely combination approaches, is clearly warranted given this long-term toxicity and discontinuation data, with the goal of maximizing ibrutinib benefit while minimizing toxicity.

With this 5-year update of single-agent ibrutinib therapy, we have reached a median PFS in patients with relapsed/refractory disease, as well as a median duration on therapy in previously untreated older patients. Both represent a significant step forward in our knowledge of the natural history of ibrutinib therapy, but many questions remain for the future: mature follow-up of larger trials, outcomes in high-risk and/or young patients treated frontline, and outcomes of time-limited or combination therapy, among others. Ibrutinib data are starting to mature, but much opportunity for growth remains.

Conflict-of-interest disclosure: J.R.B. has served as a consultant for Janssen, Pharmacyclics, AstraZeneca, Sun, Redx, Sunesis, Loxo, Gilead, TG Therapeutics, Verastem, and AbbVie and receives research funding from Sun and Gilead. ∎

REFERENCES

1. O'Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. *Blood.* 2018;131(17):1910-1919.

2. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. *N Engl J Med.* 2013;369(1):32-42.

3. Brown JR. The treatment of relapsed refractory chronic lymphocytic leukemia. *Hematology Am Soc Hematol Educ Program.* 2011;2011:110-118.

4. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med.* 2000; 343(26):1910-1916.

5. Thompson PA, O'Brien SM, Wierda WG, et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. *Cancer.* 2015;121(20):3612-3621.

6. Byrd J, Hillmen P, O'Brien S, et al. Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): up to four years follow-up of the RESONATE study [abstract]. *J Clin Oncol.* 2017;35. Abstract 7510.

7. Brown JR, Hillmen P, O'Brien S, et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. *Leukemia.* 2018;32(1):83-91.

8. Kipps T, Hillmen P, Demirkan F, et al. 11q deletion (del11q) is not a prognostic factor for adverse outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treated with ibrutinib: pooled data from 3 randomized phase 3 studies [abstract]. *Blood.* 2016;128(22). Abstract 2042.

9. Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 621 ibrutinib-treated chronic lymphocytic leukemia patients in the United States: a real-world analysis [published online ahead of print 1 February 2018]. *Haematologica.* doi:10.3324/haematol.2017.182907.

10. Ghez D, Calleja A, Protin C, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. *Blood.* 2018;131(17):1955-1959.

11. Barr P, Robak T, Owen C, et al. Updated efficacy and safety from the phase 3 Resonate-2 study: ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia [abstract]. *Blood.* 2016;128(22). Abstract 234.

LYMPHOID NEOPLASIA

Comment on Ghez et al, page 1955

Ibrutinib and fungus: an invasive concern

Kerry Rogers | The Ohio State University

In this issue of *Blood*, Ghez et al report on 33 patients who developed invasive fungal infections during ibrutinib treatment, the majority of which were invasive aspergillosis, which supports the observation that fungal infections are a potential risk with ibrutinib.[1]

Also in this issue of *Blood*, O'Brien et al[2] report a 5-year experience with ibrutinib which shows continued favorable outcomes and should increase enthusiasm for this agent, but as the associated commentary by Brown[3] points out, it strengthens the need to understand early- and late-occurring toxicities. Through the extended follow-up and review of the non-trial experience, we are gaining additional knowledge regarding risks of ibrutinib, including some that were not recognized in the clinical trial population.

Ibrutinib is a disease-altering therapy for many B-cell malignancies that has been approved for 4 different cancers and chronic graft-versus-host disease. Ibrutinib is highly effective in all categories of patients with chronic lymphocytic leukemia (CLL), the most prevalent adult leukemia, and is better tolerated than other available therapies. This has led to its widespread and increasing use.

However, *Pneumocystis jirovecii* pneumonia and other opportunistic fungal infections have recently been noted in small series and case reports on ibrutinib treated patients.[4,5] This raises concern that ibrutinib may increase the risk for these infections because they are uncommon in CLL patients. Adding to the concern is an alarming observation from an ibrutinib combination study in primary central nervous system lymphoma that 39% of patients developed invasive aspergillosis.[6]

This information prompted Ghez et al to conduct a survey of centers in the French Innovative Leukemia Organization to identify patients who were diagnosed with invasive fungal infections while taking ibrutinib. They found a total of 33 cases: 27 aspergillosis, 4 disseminated cryptococcosis, 1 mucormycosis, and 1 pneumocystis pneumonia. Unsurprisingly, all but 3 of these cases were in CLL patients because CLL is likely to be the most common indication for prescribing ibrutinib. They report a high rate of central nervous system involvement in the patients with aspergillosis (11 of 27). This is consistent

Ibrutinib may permit invasive fungal infections through multiple effects. These include inhibition of alveolar macrophage, neutrophil, T-cell, and platelet function as well as alterations in the chemoattractant and cytokine environment. DC, dendritic cells; NETs, neutrophils extra-cellular traps; PMN, polymorphonuclear neutrophils; ROS, reactive oxygen species; SOD, superoxyde dismutase; Th, T helper. See supplemental Figure 1 in the article by Ghez et al that begins on page 1955.

with a recently reported retrospective cohort study that found an incidence of 4.1% for opportunistic infections during ibrutinib treatment, and aspergillosis accounted for the majority, which adds to the mounting evidence that ibrutinib use is associated with these highly morbid infections.[7]

It is notable that the majority of patients in the French cohort had at least 1 additional factor that increased their risk for fungal infections. This included well-recognized risk factors such as chemotherapy within the last 6 months, neutropenia, and corticosteroid use. The implication was that use of ibrutinib alone may be insufficient to permit fungal infections so a second factor is necessary. This information can be used to identify which patients are at highest risk for this complication.

Interestingly, 85% of fungal infections occurred in the first 6 months after starting ibrutinib; 61% occurred in the first 3 months. This suggests that risk for invasive fungal infections may decrease with longer exposure to ibrutinib. It has previously been shown that infections decrease 6 months after the start of ibrutinib treatment concomitant with an increase in levels of immunoglobulin A.[8] Perhaps the later developing immune effects of ibrutinib are less suppressive of the functions required for defense against invading fungi or they may strengthen these defenses. Whether these later immune effects are truly a global immune reconstitution or a more favorable form of immune dysregulation remains to be seen.

The mechanism by which ibrutinib permits fungal infections is of great interest. The main target of ibrutinib is BTK, which is important for the normal function of B cells.[9] However, it is unlikely that inhibition of BTK in B cells alone accounts for this risk, because patients with X-linked agammaglobulinemia who have a genetic deficiency of BTK do not commonly experience invasive fungal infections. It is more probable that inhibition of BTK in other cells within a mature immune system (such as macrophages) and inhibition of the other targets of ibrutinib play a role because ibrutinib inhibits several kinases important for immune function such as ITK and TEC.[9,10] The potential for different mechanisms by which ibrutinib may allow establishment of an invading fungal organism into an infection are shown in the figure. It is important to determine whether fungal infections will also be observed with more selective BTK inhibitors such as acalabrutinib.

These findings by Ghez et al, in conjunction with other reports, establish an association between ibrutinib and invasive fungal infections. This leads to several important

clinical questions such as which patients are best selected for ibrutinib treatment and who would benefit from prophylaxis. The overall incidence of these infections is low enough that routine prophylaxis for all patients with CLL who are taking single-agent ibrutinib would be excessive, especially given the cost and drug interactions with ibrutinib. However, prophylaxis is reasonable in select patients with additional risk factors. More work such as the 5-year follow-up by O'Brien et al[2] will need to be done to better identify who might benefit from prophylaxis and to define the secondary factors that add to risk.

Clinicians need to stay vigilant for signs of aspergillosis and other fungal infections in their ibrutinib-treated patients so that these serious infections are rapidly diagnosed and treated. Although it is important to understand the risks of any therapy, ibrutinib remains the best option for treating the malignancies of many patients and, in most cases, risk for invasive fungal infections should not deter its use.

Conflict-of-interest disclosure: The author declares no competing financial interests. ■

REFERENCES

1. Ghez D, Calleja A, Protin C, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. *Blood*. 2018;131(17):1955-1959.

2. O'Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. *Blood*. 2018; 131(17):1910-1919.

3. Brown JR. Ibrutinib: coming of age? *Blood*. 2018;131(17):1880-1882.

4. Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. *Blood*. 2016;128(15):1940-1943.

5. Chamilos G, Lionakis MS, Kontoyiannis DP. Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways. *Clin Infect Dis*. 2018;66(1):140-148.

6. Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. *Cancer Cell*. 2017;31(6):833-843.e5.

7. Rogers KA, Luay M, Zhao Q, et al. Incidence and type of opportunistic infections during ibrutinib treatment at a single academic center [abstract]. *Blood*. 2017;130(Suppl 1). Abstract 830.

8. Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. *Blood*. 2015;126(19):2213-2219.

9. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. *Proc Natl Acad Sci USA*. 2010; 107(29):13075-13080.

10. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. *Blood*. 2013;122(15): 2539-2549.

RED CELLS, IRON, AND ERYTHROPOIESIS

Comment on Antoniani et al, page 1960

# A chance to cut (the genome) is a chance to cure

Kara E. Montbleau and Vijay G. Sankaran | Boston Children's Hospital

In this issue of *Blood*, Antoniani et al identify an innovative genome editing approach to induce fetal hemoglobin (HbF), which may eventually lead to therapeutic strategies for ameliorating or curing sickle-cell disease (SCD) and β-thalassemia.[1]

Significant advances have been made in deciphering the molecular underpinnings of hemoglobin switching. These findings hold substantial promise for being able to identify improved approaches for HbF induction to treat SCD and β-thalassemia.[2] However, for patients with these diseases, treatment remains predominantly palliative, with allogeneic hematopoietic stem cell (HSC) transplantation being the only curative therapy available. Experimental gene therapy has shown promise, but these approaches have a number of limitations, including concerns about the inability to produce sufficient hemoglobin by randomly integrating lentiviral transgenes. With the recent explosion of genome editing tools, including clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) (CRISPR/Cas9), there is potential for endogenous correction of pathogenic mutations, which could overcome the challenges present with HSC transplantation or gene therapy.

The hematopoietic system, in particular, is uniquely poised to host major advances in genome editing. Pursuing this strategy in HSCs circumvents many current obstacles

Induction of HbF by a genome editing-based deletion can ameliorate SCD. This illustration depicts the human β-globin locus on chromosome 11 (chr11) with a 3.5-kb silencer region upstream of the δ-globin gene. Typical deletions implicated in HPFH and δβ-thalassemia, as well as the Corfu thalassemia deletion, are illustrated below the locus. The schematic shows that disruption of the silencer region, in addition to the δ- and β-globin genes, using genome editing tools (depicted as scissors) can lead to a robust elevation in HbF production and ameliorate the SCD phenotype. HSs, hypersensitivity sites; 3'HS1, downstream hypersensitivity site; LCR, locus control region. Professional illustration by Patrick Lane, ScEYEnce Studios.